Metformin's Second Act: From Diabetes Pill to Longevity Candidate

The reframing is striking. A 2025 review in Cancers describes metformin as undergoing a renaissance — no longer just a glucose-lowering drug, but a prototype gerotherapeutic and immunometabolic adjuvant: a molecule that appears to nudge the same biological levers implicated in aging and cancer. The authors synthesize decades of mechanistic work alongside data from landmark trials, and the picture that emerges is genuinely interesting. It is also, importantly, incomplete.

That distinction matters. Headlines have a habit of compressing "promising" into "proven," and metformin has been on the receiving end of more than its share of overreach. So let's walk through what the evidence actually says — and what it doesn't — for women thinking carefully about the back half of life.

Aging, in the modern biological view, is not a single process but a network of intertwined ones: chronic low-grade inflammation, mitochondrial drift, accumulating senescent cells, epigenetic noise, an immune system that grows both irritable and inattentive. Drugs that meaningfully touch several of these levers at once are rare. Metformin, somewhat improbably, appears to be one of them.

According to the Cancers review, metformin modulates an integrated network of metabolic, immunological, microbiome-mediated, and epigenetic pathways that overlap with the recognized hallmarks of aging and cancer biology. In plain language: it doesn't just lower blood sugar. It seems to quiet some of the background hum that drives age-related disease.

That mechanistic breadth is the reason serious researchers — not wellness influencers — have spent years trying to design a trial big enough to test whether metformin can actually extend the years a person spends in good health.

Three trials anchor the clinical case. The first is UKPDS, the long-running U.K. diabetes study that first signaled metformin could reduce cardiovascular events in people with type 2 diabetes — a finding that has shaped prescribing for a generation. The second, CAMERA, looked at cardiometabolic markers in non-diabetic patients and helped fuel interest in metformin's effects beyond glucose control.

The third — and the one the longevity field is genuinely waiting on — is TAME (Targeting Aging with Metformin). TAME is designed to test whether metformin can delay the onset of multiple age-related diseases at once, rather than treating each in isolation. If it succeeds, it won't just be a result about a drug. It will be the first regulatory-grade evidence that aging itself can be slowed by a pharmaceutical. That is a very big if, and the trial is ongoing.

In oncology, separate trials including MA.32 and METTEN are evaluating metformin's influence on progression-free survival and tumor response, particularly as an adjuvant alongside standard cancer therapy. The Cancers review also notes clinical data suggesting metformin can reduce cancer incidence, enhance immunotherapy outcomes, delay multimorbidity, and reverse biological age markers — a remarkable list, and one that should be read in the spirit it was written: as a synthesis of accumulating signals, not a finished verdict.

One of the more provocative claims in the 2025 review is that metformin appears to reverse certain biological age markers — the epigenetic and metabolic readouts researchers use as proxies for how old your cells "act," as opposed to how old your driver's license says you are. This is the kind of finding that lights up longevity Twitter. It deserves a calmer reading.

Biological-age clocks are still maturing as a science. Different clocks disagree with one another. A drug that moves a clock is not the same as a drug that adds healthy years, and the field has not yet shown that nudging these markers reliably translates into longer healthspan in people who weren't sick to begin with. The signal is real and worth pursuing. It is not yet a recommendation.

For women navigating midlife and beyond, the honest position is this: metformin is one of the most studied, lowest-cost, longest-tolerated drugs in modern medicine, and it is being investigated with unusual seriousness as a possible tool for healthy aging. It is also a prescription drug with real side effects, real contraindications, and — for healthy adults without diabetes — no current regulatory indication for longevity.

If you live with type 2 diabetes, prediabetes, PCOS, or another condition for which metformin is already indicated, the conversation with your clinician is straightforward and well-trodden. If you are healthy and curious about metformin as a longevity tool, the conversation is different, more speculative, and one only your own physician can have with you — ideally with the TAME trial and its eventual readout in mind.

Metformin's second act is being written in real time. The most useful thing a reader can do right now is neither dismiss it nor rush it. Watch the trials. Ask good questions. And remember that the most powerful longevity interventions we have today — strength, sleep, protein, social connection, hormone-informed care — are still the ones with the deepest evidence behind them.